Clearmind Medicine INC. (CMND) SEC Filings — 2025
50 SEC filings for Clearmind Medicine INC. (CMND) in 2025.
Filings
- Clearmind Medicine INC. 6-K Filing — 6-K · Dec 31, 2025
- Clearmind Medicine Reflects on 2025 Progress — 6-K · Dec 29, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Dec 16, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Dec 12, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Dec 10, 2025
- Clearmind Medicine Fails Nasdaq Equity Rule — 6-K · Dec 5, 2025
- Clearmind Medicine Raises $1.6M in Direct Offering — 6-K · Dec 3, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Dec 2, 2025
- Clearmind Medicine Schedules Shareholder Meeting — 6-K · Nov 28, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Nov 26, 2025
- Clearmind Medicine Starts Patient Enrollment in Alcohol Use Disorder Trial — 6-K · Nov 25, 2025
- Clearmind Medicine Trial Continues After Safety Review — 6-K · Nov 24, 2025
- Clearmind Medicine Expands Alcohol Use Disorder Trial — 6-K · Nov 20, 2025
- Clearmind Medicine Raises $2.185M in Direct Offering — 6-K · Nov 19, 2025
- Clearmind Medicine Reports Positive Phase I/IIa Trial Results — 6-K · Nov 18, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Nov 17, 2025
- Clearmind Medicine INC. 6-K Filing — 6-K · Nov 13, 2025
- Clearmind Medicine Patent for Depression Treatment Published — 6-K · Nov 12, 2025
- Clearmind Medicine Faces Nasdaq Delisting Risk — 6-K · Nov 6, 2025
- Clearmind Expands IP for Depression Drug in South Korea — 6-K · Nov 5, 2025
- Clearmind Medicine Publishes US Patent App for MEAI Therapy — 6-K · Oct 31, 2025
- Clearmind Medicine Completes Phase I/IIa Trial Cohort — 6-K · Oct 30, 2025
- Clearmind Medicine Appoints Chief of Global Impact — 6-K · Oct 27, 2025
- Clearmind Medicine Completes Patient Enrollment for AUD Trial — 6-K · Oct 21, 2025
- Clearmind Medicine Patent Targets Binge Disorders — 6-K · Oct 20, 2025
- Clearmind Medicine Convenes Inaugural Scientific Advisory Board — 6-K · Sep 25, 2025
- Clearmind Medicine Secures $10M for Strategic Opportunities — 6-K · Sep 19, 2025
- Clearmind Medicine Secures Up to $10M Via Convertible Notes — 6-K · Sep 17, 2025
- Clearmind Medicine Files Interim Financials for July 31, 2025 — 6-K · Sep 11, 2025
- Clearmind Medicine Patents Obesity & Blood Sugar Therapy — 6-K · Aug 7, 2025
- Clearmind Medicine Gets IRB Approval for AUD Trial — 6-K · Aug 5, 2025
- Clearmind Medicine Files Patent for Weight Loss & Fatty Liver Therapy — 6-K · Jul 30, 2025
- Clearmind Medicine Updates Corporate Presentation — 6-K · Jul 29, 2025
- Clearmind Expands Alcohol Use Trial — 6-K · Jul 15, 2025
- Clearmind Medicine Gets IRB Approval for AUD Trial — 6-K · Jul 3, 2025
- Clearmind Medicine Doses First Patient in Alcohol Use Disorder Trial — 6-K · Jun 30, 2025
- Clearmind Expands AUD Trial, Targets Multibillion-Dollar Market — 6-K · Jun 27, 2025
- Clearmind Medicine Expands Alcohol Use Disorder Trial in Israel — 6-K · Jun 23, 2025
- Clearmind Medicine Hires Lobbying Firm for Psychedelic Drugs — 6-K · Jun 12, 2025
- Clearmind Medicine Enrolls First Patient in Alcohol Use Disorder Trial — 6-K · Jun 5, 2025
- Clearmind Medicine Secures European Patent for Cocaine Addiction Therapy — 6-K · May 12, 2025
- Clearmind Medicine Files International Patent for Eating Disorder Treatment — 6-K · Apr 25, 2025
- Clearmind Medicine Starts Alcohol Use Disorder Trial — 6-K · Apr 23, 2025
- Clearmind Medicine Secures US Patent for Binge Behavior Treatment — 6-K · Apr 17, 2025
- Clearmind Medicine Starts US Trial for Alcohol Use Disorder — 6-K · Apr 10, 2025
- Clearmind Medicine Patents Next-Gen Psychedelics for Mental Health — 6-K · Apr 8, 2025
- Clearmind Launches EDC System for MEAI Trial — 6-K · Apr 1, 2025
- Clearmind Medicine's CMND-100 Trial Advances with US Drug Arrival — 6-K · Mar 24, 2025
- Clearmind Explores Intranasal Psychedelic Delivery — 6-K · Mar 19, 2025
- Clearmind Medicine Starts First Human Trial for CMND-100 — 6-K · Mar 18, 2025